Published in
American Society of Hematology, Blood Advances, 19(1), p. 1551-1564, 2017
DOI: 10.1182/bloodadvances.2017008342
Links
Tools
Patient-derived antibody recognizes a unique CD43 epitope expressed on all AML and has antileukemia activity in mice
Journal article published in 2017 by
Marijn A. Gillissen,
Greta de Jong,
Martijn Kedde,
Etsuko Yasuda,
Sophie E. Levie,
Gemma Moiset,
Paul J. Hensbergen,
Arjen Q. Bakker,
Koen Wagner,
Jullien Villaudy,
Pauline M. van Helden,
Hergen Spits,
Mette D. Hazenberg 
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 
Abstract
Key Points AT1413 is a monoclonal antibody isolated from a cured patient with AML that recognizes CD43s, a novel epitope expressed by AML and MDS blasts. AT1413 eliminates CD43s-expressing leukemic blasts in vitro and in vivo and may have potential as a therapeutic antibody.